

Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab

NCT07006532

Status	RECRUITING
Phase	Not Applicable
Sponsor	Shahid Beheshti University of Medical Sciences
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (5)

- Signed written informed consent
- eGFR > 25 cc/min
- Chronicity index < 8
- IFTA $< 40\%$
- EBV IgG positive

Exclusion (4)

- Active or recurrent infections
- History of malignancy, unless in remission for more than 2 years with no relapse
- abnormal liver function tests
- Platelet $< 100,000$

Locations (1 total)

Nooshin Dalili, Tehran, Iran